Mitochondria in Motion, Inc

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Mitochondria in Motion, (MiM) is a biotech Co. that will clinically advance and commercialize first-in-class mitofusin activators which improve mitochondrial function by correcting mitochondrial dys-dynamism in genetic, traumatic, and iatrogenic neurodegenerative diseases (ND). Our first indication is Charcot-Marie-Tooth disease (CMT)2A, caused by mutations of our drugs’ target, mitofusin (MFN)2. Loss of MFN2 function suppresses mitochondrial fusion and trafficking. With no disease-altering therapy, most CMT2A affected children are permanently non-ambulatory by age 20. Similar neuronal mitochondrial phenotypes are observed in CMT1, ALS, HD, frontotemporal dementia, and CIPN. MiM’s compounds bind to MFNs, altering their conformation to enhance activity, and thereby mitochondrial fitness. As the first compounds that directly improve mitochondrial dynamism, approval of mitofusin activators opens the door to a new and fundamentally different therapeutic approcach to ND.
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
Missouri
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
Mitofusin Agonists
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Scientific Director
Mitochondria in Motion